Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients

Figure 3

Dynamic change and survival analysis of TIGIT and DNAM-1 on Foxp3+ γδ T cells in AML patients. (a) Pairwise comparisons of Foxp3+ and TIGIT+Foxp3+ γδ T cells in eight AML patients who achieved CR. (b) Pairwise comparisons of Foxp3+ and DNAM-1 on Foxp3+ γδ T cells in eight AML patients who achieved CR. (c) Summary of the dynamic changes in the Foxp3+, TIGIT+Foxp3+, and DNAM-1+Foxp3+ γδ T cell subsets in AML patients before and after treatment. a: Foxp3+ γδ T cells before treatment; b: Foxp3+ γδ T cells after treatment; c: TIGIT+Foxp3+ γδ T cells before treatment; d: TIGIT+Foxp3+ γδ T cells after treatment; e: DNAM-1+Foxp3+ γδ T cells before treatment; f: DNAM-1+Foxp3+ γδ T cells after treatment. (d) Comparison of OS curves of de novo AML patients based on TIGIT+Foxp3+ γδ T cell expression. The red line indicates high TIGIT+Foxp3+ expression; the blue line indicates low TIGIT+Foxp3+ expression.

(a)

(b)

(c)

(d)